This week, we will discuss the best schedule for tapering steroids in adult patients with podocytopathies (MCD/FSGS).

¿Podemos reducir el uso de esteroides tras la remisión?

Can steroid tapering be shorter after remission in adults with sensitive podocytopathy?

NephJC is now more than twelve years old- and it’s amazing to see how far a simple idea has grown. We started with a handful of nephrologists on Twitter (yeah, we still call it that) choosing a paper ...

On FRIDAY night, October 23rd, NephJC will host another legendary NephJC Night during ASN Kidney Week

On FRIDAY night, October 23rd, NephJC will host another legendary NephJC Night during ASN Kidney Week

ALT: Simmering Lemon Slices for Syrup

Help keep NephJC a vital, original, and unbiased source of medical education.

From 2-year delay to simultaneous publication the journey from MENTOR to MAJESTY

This week, we will discuss the use of LLMs for the diagnosis of complex nephrology cases. Can AI help nephrologists nail the correct diagnosis?

¿Puede la IA mejorar la toma de decisiones clínicas en nefrología?

Can AI boost clinical decision-making in nephrology?

Once a patient with septic shock has received the first liter, what comes next? ARISE FLUIDS reshapes the ED shock strategy before 30 mL/kg: more fluid or earlier vasopressors?

First trial in pregnancy and CKD after 30 years - aiming to test feasibility of nitrate administration in pregnant women with CKD

PUSH Water to prevent kidney stones…or not

This week, we will discuss

MERCURI-2 reports that dapagliflozin cuts postoperative AKI after cardiac surgery, but the headline result is mostly a urine-output story, not a creatinine one. That matters: urine output after surger...

¿MERCURI-2 desafía la forma en que utilizamos los iSGLT2?

Does MERCURI-2 challenge how we use SGLT2i in post-operative patients?

Iptacopan decreases proteinuria, now we get the 24-month eGFR data in patients with IgA Nephropathy.

Metabolic acidosis is common in critically ill patients and is associated with organ dysfunction and death. Sodium bicarbonate is used to correct acidemia, but its benefit in patients with metaboli...

This week, we will discuss SODaBIC trial: with ICU acidosis driven by multiple overlapping mechanisms, is bicarbonate infusion supported by robust evidence, or does it persist mainly out of habit rath...

Cristina Popa dissects the FIND-CKD extras: GN subgroup and INFINITY analysis

FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effect...

¿Está la finerenona lista para ir más allá de la diabetes? El estudio FIND-CKD recien llegado del #ERA26, es el primer ensayo fase 3 que demuestra protección renal con finerenona en pacientes con ERC...

Is finerenone ready to move beyond diabetes? The FIND-CKD phase 3 arrived from the #ERA26 and is the first one to show kidney protection with finerenone in non-diabetic CKD. The next challenge is no...

Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD. Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown ben...

¿Puede rivaroxabán reducir los eventos cardiovasculares en la ERC avanzada? El estudio TRACK comparó rivaroxabán a dosis bajas frente a placebo en pacientes con ERC estadio 4–5 y enfermedad renal en ...

Can rivaroxaban reduce cardiovascular events in advanced CKD? The TRACK trial compared low-dose rivaroxaban with placebo in patients with stage 4–5 CKD and dialysis-dependent kidney failure at high c...

Does Dual BAFF/APRIL Blockade with Telitacicept Reduce Proteinuria in Persistent Proteinuric IgA Nephropathy?

Time to fix the sodium! The Hyponatremia Intervention Trial

Kidney Int . 2026 Apr;109(4):738-749. doi: 10.1016/j.kint.2025.12.024. Epub 2026 Jan 20. A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment i...

Fresh from the #ERA26 Late-Breaking Clinical Trials, the MAJESTY study compared obinutuzumab with tacrolimus and raises important questions about the future of anti-CD20 therapy. 👑 Is deeper B-cell d...

Recién llegado desde #ERA26, el estudio MAJESTY comparó obinutuzumab frente a tacrolimus y plantea importantes interrogantes sobre el futuro de las terapias anti-CD20 en la nefropatía membranosa prima...

This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy

Is measured GFR more accurate than eGFR for forecasting adverse outcomes?